Alzheimer’s disease (AD) remains one of the most critical unmet clinical challenges in contemporary medicine. It encompasses a heterogeneous group of progressive neurodegenerative processes that culminate in functional decline and disability in older adults.
Clinical decline initially manifests as mild language impairments and affective alterations, and subsequently progresses to profound mnemonic dysfunction and an almost complete loss of functional autonomy.
The 2025 AD therapeutic development pipeline reflects substantive expansion and innovation, underscoring ongoing progress in identifying and evaluating novel and improved treatment options for individuals living with AD.
source